Veterans, individuals with kidney disease being asked to test new app

Veterans and other individuals managing kidney disease are being asked to test a new nutrition-tracking mobile application designed to help kidney patients.

The American Association of Kidney Patients (AAKP) announced it’s partnering with the American Society of Nephrology (ASN) and U.S. Department of Veteran Affairs (VA) to encourage patients to test the new MyKidneyNutrition app before it launches.

The app—developed by the ASN and the VA—allows patients to track their daily activities like nutrition, fitness and medication information. The organizations hope the app will help patients lead healthier and “more kidney-friendly” lives.

“ASN is honored to be able to once again collaborate with AAKP through the testing of the MyKidneyNutrition app,” former ASN President Sharon Moe, MD, said in a press release. “We look forward to the feedback we receive from kidney patients that volunteer to test the app before its public release, thus ensuring that the MyKidneyNutrition app truly address the needs of kidney patients.”

The organizations plan to identify both veterans and non-veterans to test the app before it launches. People interested in testing the app should contact Erin Kahle, AAKP director of stakeholder operations, at ekahle@aakp.org.

“Participating in the testing of this mobile app is an important step in making a real difference in the future of kidney care for both veterans and other individuals impacted by kidney disease,” Edward Hickey III, AAKP Veterans Health Initiative chair, said. “Veterans are natural consumers of technology and the ability to use a new tool to manage their kidney health is a welcome innovation.”

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.